Cuál es el precio por Freeline Therapeutics Holdings plc (FRLN)

Precio por Freeline Therapeutics Holdings plc (FRLN) es de$6.48

Cuál es la capitalización de mercado por Freeline Therapeutics Holdings plc (FRLN)

Capitalización de mercado por Freeline Therapeutics Holdings plc (FRLN) es $15.41M

Freeline Therapeutics Holdings plc (FRLN) Dividendos

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Año	Dividendo (ajustado por splits de acciones)	Cambiar
Not enough data for the provided dates.

Año

Dividendo (ajustado por splits de acciones)

Cambiar

Not enough data for the provided dates.

Año	Dividendo	Cambiar
Not enough data for the provided dates.

Año

Dividendo

Cambiar

Not enough data for the provided dates.

Empresa	Número de pagos de dividendos	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Lonza Group AG LONN.SW	0.00%	CH
UCB S.A. UCB.BR	29.00%	BE

Empresa

Número de pagos de dividendos

País